Abstract
Presented at the Great Lakes Pharmacy Residents Conference. West Lafayette, IN: April 2024.
This retrospective, cross-sectional study found that nearly all patients were not administered pulmonary function testing prior to treatment with COPD triple therapy (inhaled corticosteroid plus long-acting muscarinic-antagonist plus long-acting beta-2-agonist). Additionally, the vast majority did not have a documented elevated eosinophil count. These represent good opportunities to optimize population-based care for COPD patients.
Document Type
Conference Proceeding
Publication Date
4-2024
Recommended Citation
Offerle, Jessica PharmD, "Evaluation of triple therapy use for COPD" (2024). Pharmacy Residency. 26.
https://researchrepository.parkviewhealth.org/pharmresidency/26